Duckert F
Schweiz Med Wochenschr. 1975 Jun 14;105(24):783-4.
The availability of factor VIII and factor IX concentrates has considerably improved substitution therapy in hemophilia A and B respectively. The desired activity levels and the corresponding factor VIII or factor IX dosage are indicated. Antifibrinolyics have a favorable action when given simultaneously, though hematuria is an absolute contraindication for antifibrinolytic treatment. The administration of factor IX concentrate in case of hemorrhage due to oral anticoagulation or to liver disease, or in newborns, should be used in emergency situations only, since this material may provoke either thrombosis or disseminated intravascular coagulation. Transmission of hepatitis is also possible.
分别有了凝血因子 VIII 和凝血因子 IX 浓缩剂后，血友病 A 和 B 的替代疗法有了显著改善。文中给出了所需的活性水平及相应的凝血因子 VIII 或凝血因子 IX 剂量。同时使用抗纤溶药物有良好效果，不过血尿是抗纤溶治疗的绝对禁忌证。因口服抗凝药或肝病导致出血时，或在新生儿中，仅在紧急情况下才使用凝血因子 IX 浓缩剂，因为这种物质可能引发血栓形成或弥散性血管内凝血。肝炎传播也有可能。
